Malignant mesothelioma is a universally lethal cancer that is increasing in incidence worldwide. There is a dearth of effective therapies, with only one treatment (pemetrexed and cisplatin combination chemotherapy) approved in the past 13 years. However, the past 5 years have witnessed an exponential growth in our understanding of mesothelioma pathobiology, which is set to revolutionize therapeutic strategies. From a genomic standpoint, mesothelioma is characterized by a preponderance of tumour suppressor alterations, for which novel therapies are currently in development. Other promising antitumour agents include inhibitors against angiogenesis, mesothelin and immune checkpoints, which are at various phases of clinical trial testing.

恶性间皮瘤是一种普遍致命的癌症，在世界范围内发病率正在增加。缺乏有效的疗法，在过去的13年中仅批准了一种疗法（培美曲塞和顺铂联合化疗）。然而，在过去的5年中，我们对间皮瘤病理生物学的了解呈指数增长，这将彻底改变治疗策略。从基因组的角度来看，间皮瘤的特征是大量的肿瘤抑制因子改变，目前正在开发新的疗法。其他有希望的抗肿瘤药包括抗血管生成的抑制剂，间皮素和免疫检查点，它们处于临床试验测试的各个阶段。